On the basis of these findings in vitro, clinical trials of survivin-2B80-88 peptide immunotherapy have been conducted for advanced cancers such as colorectal cancer, breast cancer, lung cancer, and oral cancer [24,26], in which tumor regression (partial response) was observed in certain cases. Here, BIRC5 is linked to breast cancer.